TS-ONE Capsule ဆေး
ဆရာဝန်ကို မမေးပါ။ ဖတ်လိုကဖတ်၊ မဖတ်လိုက နေနိုင်တယ်။
TS-ONE Capsule 20 = Tegafur 20 mg, Gimeracil 5.8 mg and Oteracil potassium 19.6 mg.
TS-ONE Capsule 25 = Tegafur 25 mg, Gimeracil 7.25 mg and Oteracil potassium 24.5 mg.
ဝမ်းပျက်၊ အနီပြင်ထွက်၊ လျှာနာခြင်းတွေ ဆေးစသောက်ပြီး ၂၁ ရက်အကြာမှာ ဖြစ်တယ်။ အစောဆုံး ၉ ရက်မှာ ဝမ်းပျက်တယ်။
advanced gastric cancer အဆင့်နောက်ကျတဲ့ အစာအိမ်ကင်ဆာမှာ ပေးတယ်။ ခွဲမဖြစ်တဲ့ အစာအိမ်ကင်ဆာကို Cisplatin နဲ့လည်း တွေဲပေးတယ်။
Non-Small Cell Lung Cancer အဆုတ်ကင်ဆာမျာလည်း Carboplatin နဲ့တွဲပေးတယ်။
Colorectal Cancer အူမကြီးကင်ဆာမှာ Oxaliplatin သို့မဟုတ် Irinotecan နဲ့တွဲပေးတယ်။
Pancreatic Cancer သရက်ရွက်ကင်ဆာမှာ အခုဆေးတမျိုးတည်း ပေးတယ်။
ဘယ်လူနာကို ဆေးအလေးချိန် 10 mg နဲ့ 40 mg ဘယ်လောက်ပေးမလဲ ချိန်ဆပေးပါတယ်။
အောက်ကစာတွေကို ဘာသာမပြန်တော့ပါ။
Monotherapy: TS-ONE should be administered twice daily, after breakfast and after the evening meal, for 28 consecutive days, followed by a 14-day rest. This is regarded as one course of the regimen.
Combination Therapy: Non-Small Cell Lung Cancer: TS-ONE is recommended to be administered twice daily, after meals, for 14 consecutive days, in combination with carboplatin (AUC 5) on Day 1. This treatment is repeated every 3 weeks.
Colorectal Cancer: For 1st line of treatment, TS-ONE is recommended to be administered twice daily, after meals, for 14 consecutive days, in combination with oxaliplatin 130 mg/m2 on Day 1 as a 2 hour intravenous infusion. This treatment is repeated every 3 weeks.
For 2nd line of treatment, TS-ONE is recommended to be administered twice daily, after meals, from Day 1 to 14, in combination with irinotecan 125 mg/m2 on Days 1 and 15. This treatment is repeated every 4 weeks.
Gastric Cancer: TS-ONE is recommended to be administered twice daily, after meals, for 21 consecutive days and 60 mg/m2 intravenous infusion of cisplatin on Day 8, followed by a 14 days rest. This treatment is repeated every 5 weeks.
Use in the Elderly: Since elderly patients often have decreased physiological functions, TS-ONE should be administered with care.
Pediatric Use: The efficacy and safety of TS-ONE in children and adolescents have not been established. Therefore, use in this patient population is not recommended
ဒေါက်တာတင့်ဆွေ
Comments
Post a Comment